Emily Leproust Sells 1,605 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 1,605 shares of Twist Bioscience stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $34.56, for a total value of $55,468.80. Following the sale, the chief executive officer owned 874,313 shares in the company, valued at $30,216,257.28. This trade represents a 0.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock traded down $1.22 during trading on Tuesday, reaching $33.84. The company’s stock had a trading volume of 804,463 shares, compared to its average volume of 1,350,107. The company has a 50-day moving average price of $31.02 and a two-hundred day moving average price of $31.19. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $55.33. The firm has a market cap of $2.07 billion, a PE ratio of -25.83 and a beta of 2.24. The company has a current ratio of 3.64, a quick ratio of 3.33 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05). Twist Bioscience had a negative return on equity of 27.40% and a negative net margin of 20.63%.The company had revenue of $99.01 million for the quarter, compared to analyst estimates of $97.40 million. On average, analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the business. Quarry LP purchased a new position in shares of Twist Bioscience during the 3rd quarter worth about $28,000. Smartleaf Asset Management LLC increased its position in Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after purchasing an additional 442 shares during the last quarter. National Bank of Canada FI purchased a new position in Twist Bioscience during the third quarter worth approximately $46,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after purchasing an additional 302 shares during the last quarter. Finally, Geneos Wealth Management Inc. purchased a new stake in shares of Twist Bioscience during the 2nd quarter valued at $97,000.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on TWST shares. Stephens initiated coverage on Twist Bioscience in a report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday. Barclays boosted their price objective on shares of Twist Bioscience from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Finally, Evercore ISI lowered their price target on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a report on Tuesday, October 7th. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus target price of $44.88.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.